Samarth Kulkarni Crispr Therapeutics Ag (CRSP) insider trading activity

Samarth Kulkarni is Chief Executive Officer of CRISPR Therapeutics AG. Currently has a direct ownership of 195,085 shares of CRSP, which is worth approximately $6.64 Million. The most recent transaction as insider was on Dec 01, 2019, when has been sold 741 shares (Common Shares) at a price of $71.65 per share, resulting in proceeds of $53,093. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 195K

0.11% 3M change

6.26% 12M change

Total Value Held $6.64 Million

Samarth Kulkarni Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 01 2019	SELL Payment of exercise price or tax liability	$53,093 $71.65 p/Share	741 Reduced 0.45%	164,320 Common Shares
Sep 01 2019	SELL Payment of exercise price or tax liability	$34,195 $46.21 p/Share	740 Reduced 0.45%	165,061 Common Shares
Jun 17 2019	SELL Open market or private sale	$920,000 $46.0 p/Share	20,000 Reduced 10.76%	165,801 Common Shares
Jun 17 2019	BUY Exercise of conversion of derivative security	$36,200 $1.81 p/Share	20,000 Added 9.72%	185,801 Common Shares
Jun 01 2019	SELL Payment of exercise price or tax liability	$26,357 $35.57 p/Share	741 Reduced 0.44%	165,801 Common Shares
Apr 29 2019	SELL Open market or private sale	$840,600 $42.03 p/Share	20,000 Reduced 10.72%	166,542 Common Shares
Apr 29 2019	BUY Exercise of conversion of derivative security	$36,200 $1.81 p/Share	20,000 Added 9.68%	186,542 Common Shares
Mar 01 2019	SELL Payment of exercise price or tax liability	$29,898 $39.97 p/Share	748 Reduced 0.45%	166,542 Common Shares
Dec 07 2018	BUY Exercise of conversion of derivative security	$38,915 $1.81 p/Share	21,500 Added 11.39%	167,290 Common Shares
Dec 01 2018	SELL Payment of exercise price or tax liability	$28,403 $38.33 p/Share	741 Reduced 0.51%	145,790 Common Shares
Sep 01 2018	SELL Payment of exercise price or tax liability	$41,992 $56.67 p/Share	741 Reduced 0.5%	146,531 Common Shares
Jun 04 2018	SELL Payment of exercise price or tax liability	$49,743 $67.13 p/Share	741 Reduced 0.5%	147,819 Common Shares
Jun 01 2018	SELL Open market or private sale	$1,031,700 $68.78 p/Share	15,000 Reduced 9.17%	148,560 Common Shares
Jun 01 2018	BUY Exercise of conversion of derivative security	$27,150 $1.81 p/Share	15,000 Added 8.4%	163,560 Common Shares
Dec 21 2017	BUY Exercise of conversion of derivative security	$27,150 $1.81 p/Share	15,000 Added 9.17%	148,560 Common Shares
Dec 01 2017	BUY Grant, award, or other acquisition	$509,873 $19.12 p/Share	26,667 Added 16.64%	133,560 Restricted Stock Units
Aug 30 2017	SELL Open market or private sale	$80,000 $20.0 p/Share	4,000 Reduced 3.61%	106,893 Common Shares
Aug 28 2017	SELL Open market or private sale	$465,164 $20.09 p/Share	23,154 Reduced 17.27%	110,893 Common Shares
Apr 27 2017	SELL Open market or private sale	$37,017 $16.78 p/Share	2,206 Reduced 1.62%	134,047 Common Shares
Apr 27 2017	BUY Exercise of conversion of derivative security	$3,993 $1.81 p/Share	2,206 Added 1.59%	136,253 Common Shares
Apr 26 2017	SELL Open market or private sale	$54,823 $16.74 p/Share	3,275 Reduced 2.38%	134,047 Common Shares
Apr 26 2017	BUY Exercise of conversion of derivative security	$5,928 $1.81 p/Share	3,275 Added 2.33%	137,322 Common Shares
Apr 25 2017	SELL Open market or private sale	$86,290 $16.87 p/Share	5,115 Reduced 3.68%	134,047 Common Shares
Apr 25 2017	BUY Exercise of conversion of derivative security	$9,258 $1.81 p/Share	5,115 Added 3.55%	139,162 Common Shares
Apr 24 2017	SELL Open market or private sale	$57,610 $16.46 p/Share	3,500 Reduced 2.54%	134,047 Common Shares

Also insider at

BDTX

Black Diamond Therapeutics, Inc. Healthcare

RPTX

Repare Therapeutics Inc. Healthcare

CNTA

Centessa Pharmaceuticals plc Healthcare

Director